Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: A prospective, 6-month observational study

Journal of Neurology

Volumn 258, Issue 10, 2011, Pages 1805-1811

  Magraner, María José ^a   Coret, Francisco ^b   Navarré, Arantxa ^b   Boscá, Isabel ^a   Simó, María ^a   Escutia, Matilde ^a   Bernad, Ana ^b   Navarro, Laura ^a   Casanova, Bonaventura ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Drug holidays; Natalizumab; Pulses of steroids

Indexed keywords

BETA1A INTERFERON; DACLIZUMAB; FINGOLIMOD; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PREDNISOLONE;

ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG SAFETY; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEROID THERAPY; TREATMENT DURATION;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PROSPECTIVE STUDIES; RECURRENCE; YOUNG ADULT;

EID: 80054764351     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-6019-8     Document Type: Article

References (23)

1. CH Polman PW O'Connor E Havrdova, et al. 2006 A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899 910 16510744 10.1056/NEJMoa044397 1:CAS:528:DC%2BD28XitVertL4%3D
2. RA Rudick WH Stuart PA Calabresi, et al. 2006 Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 911 923 16510745 10.1056/NEJMoa044396 1:CAS:528:DC%2BD28XitVertLw%3D
3. Safety report from Biogen Idec, data on file. October 2010
4. Miravalle A, Jensen R, Kinkel RP et al (2010) Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. [Epub ahead of print]
5. J Killestein A Vennegoor EM Strijbis, et al. 2010 Natalizumab drug holiday in multiple sclerosis: poorly tolerated Ann Neurol 68 392 395 20661928 10.1002/ana.22074
6. T Lenhard A Biller W Mueller I Metz J Schönberger B Wildemann 2010 Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology 75 9 831 833 20805529 10.1212/WNL.0b013e3181f07362 1:STN:280:DC%2BC3cjosFOqtA%3D%3D
7. MM Vellinga JA Castelijns F Barkhof BM Uitdehaag CH Polman 2008 Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients Neurology 70 1150 1151 17872364 10.1212/01.wnl.0000265393.03231.e5 1:STN:280:DC%2BD1c3gt1Wnsw%3D%3D (Pubitemid 351464749)
8. HP Hartung 2009 New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab Lancet Neurol 8 28 31 19081511 10.1016/S1474-4422(08)70281-3
9. DH Miller OA Khan WA Sheremata, et al. 2003 A controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 348 15 23 12510038 10.1056/NEJMoa020696 1:CAS:528:DC%2BD3sXhtlCntg%3D%3D (Pubitemid 36026342)
10. CM Dalton KA Miszkiel GJ Barker, et al. 2004 Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis J Neurol 251 407 413 15083284 10.1007/s00415-004- 0332-4 1:CAS:528:DC%2BD2cXkvVeksLw%3D (Pubitemid 38501297)
11. O Stüve PD Cravens EM Frohman, et al. 2009 Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy Neurology 72 396 401 18987352 10.1212/01.wnl.0000327341.89587.76
12. E Giannuli S Marousi I Karkanis A Graigos V Kotsi 2010 Natalizumab discontinuation after long-term administration: our own experience Mult Scler 16 S138
13. TW West BA Cree 2010 Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 68 395 399 20818793 10.1002/ana.22163
14. K Tan R Roda L Ostrow J McArthur A Nath 2009 PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids Neurology 72 1458 1464 19129505 10.1212/01.wnl.0000343510.08643.74 1:STN:280: DC%2BD1MzgsVWnsQ%3D%3D
15. SA Shelburne M Montes RJ Hamill 2006 Immune reconstitution inflammatory syndrome: more answers, more questions J Antimicrob Chemother 57 167 170 16354748 10.1093/jac/dki444 1:CAS:528:DC%2BD28XovVGgtg%3D%3D (Pubitemid 43160154)
16. M Hutchinson L Kappos PA Calabresi, et al. 2009 The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL J Neurol 256 405 415 19308305 10.1007/s00415-009-0093-1 1:CAS:528:DC%2BD1MXltlKrs78%3D
17. PW O'Connor AD Goodman L Kappos, et al. 2009 Return of disease activity after cessation of natalizumab therapy in patients with multiple sclerosis Mult Scler 15 S240
18. F Sangalli L Moiola M Radaelli V Barcella V Martinelli G Comi 2010 Starting immunomodulatand shortly after natalizumab discontinuation: initial impressions Mult Scler 16 S142
19. A Kebrat E Le Page E Leray, et al. 2010 Assessment of disease activity within 6 months after natalizumab discontinuation: and observational study of 28 consecutive relapsing-remitting multiple sclerosis patients Mult Scler 16 S128
20. I Pesci S Magnani D Carini, et al. 2010 Stopping natalizumab therapy: experience of follow-up in a MS center, FIdrenza, Italy Mult Scler 16 S153
21. A Baugmartner O Stich S Rauer 2010 Clinical and radiological diseases reactivation after cessation of long-term therapy with natalizumab Mult Scler 16 S145
22. E Cocco L Lorefice J Frau, et al. 2010 Natalizumab discontnuiation in multiple sclerosis: experience of a single center Mult Scler 16 S299
23. S Rossi G Ristori V Studer, et al. 2010 An open-label, nonrandomized, prospective, multicenter study to evaluate the safety and tolerability of glatiramer acetate 20 mg sc once daily in patients with severe relapsing-remitting multiple sclerosis that have discontinued natalizumab after 12 to 18 months therapy. Preliminary results Mult Scler 16 S133 10.1177/1352458509355069